Putting Vietnam under the microscope
This article was originally published in Scrip
You may also be interested in...
Once dubbed “the sick man of Asia,” the Philippines is now being touted by many as the ASEAN nation worthy of investment consideration. It is not to suggest there are no challenges. International companies frequently cite lack of decision-making transparency and corruption as key operating challenges, plus a bureaucracy that can slow down processes. But an ongoing increase in pharmaceutical consumption, coupled with government investment in universal health care, as well as economic and population growth, make the Philippines an interesting and attractive mid-term pharmaceutical market in Asia.
Myanmar, also known as Burma, has been getting a lot of international press coverage lately, not least because of the release from house arrest of dissident Aung San Suu Kyi, the lifting of US trade sanctions, and US President Barack Obama's high-profile visit in November 2012.
With the sixth-largest population worldwide, which is growing at 1.6% per annum, Pakistan is not for the faint-hearted. It appears to have almost everything for everybody: a good pharmaceutical market growth (5-7% annual growth), well-established local companies and relatively high private sector prices, but also price control, endemic corruption, poor intellectual property rights enforcement, counterfeits, illegal imports, relatively fast off-takes of new products and reasonably well-developed urban centres.